Categories
All News News

Vector Manufacturing Market: Opinion Leaders Highlight Key Concerns | Roots Analysis

The growing pipeline of cell and gene therapies has led to an increase in demand for high-quality gene delivery vehicles and, therefore, has created significant opportunities for companies with expertise in manufacturing viral and non-viral vectors.

In an article published last year, I discussed the growing cell and gene therapy market and how it has positively influenced the growth of the vector manufacturing market.

For More Insights Click Here

The current vector manufacturing landscape comprises of several players that claim to have the capability to develop vectors for cell and gene therapies. The infographic below summarizes the key facts associated with the vector contract manufacturing market.

In a recent market research report, Roots Analysis interviewed several key stakeholders in the vector manufacturing market to understand the key challenges that the industry is currently facing. The key stakeholders interviewed are:

  1. Menzo Havenga (Chief Executive Officer and President, Batavia Biosciences)
  2. Nicole Faust(Chief Executive Officer & Chief Scientific Officer, CEVEC Pharmaceuticals)
  3. Jeffrey Hung(Chief Commercial Officer, Vigene Biosciences)
  4. Olivier Boisteau(Co-Founder / President, Clean Cells)
  5. Laurent Ciavatti(Business Development Manager, Clean Cells)
  6. Xavier Leclerc(Head of Gene Therapy, Clean Cells)
  7. Joost van den Berg(Director, Amsterdam BioTherapeutics Unit)
  8. Bakhos A Tannous(Director, MGH Viral Vector Development Facility, Massachusetts General Hospital)
  9. Colin Lee Novick(Managing Director, CJ Partners)
  10. Cedric Szpirer(Executive & Scientific Director, Delphi Genetics)
  11. Semyon Rubinchik(Scientific Director, ACGT)
  12. Alain Lamproye(President of Biopharma Business Unit, Novasep)
  13. Astrid Brammer(Senior Manager Business Development, Richter-Helm)
  14. Brain M Dattilo(Business Development Manager, Waisman Biomanufacturing)
  15. Marco Schmeer(Project Manager, Plasmid Factory)
  16. Tatjana Buchholz(Marketing Manager, Plasmid Factory)
  17. Nicolas Grandchamp(R&D Leader, GEG Tech)

In addition, the team conducted surveys with different players involved in the vector manufacturing space. The figure below summarizes the details of the players involved in the survey.

The key trends that the team unfolded in the discussions are highlighted below:

  1. Cost of manufacturing viral vectors is still significantly high
  2. There are several challenges associated with production output
  3. Stringent regulatory requirements exist for conducting human clinical trials
  4. The industry is facing concerns realted to final product contamination
  5. There is a need for changes in the operational models to sustain market growth
  6. The industry has witnessed a growing preference to outsource vector manufacturing operations
  7. Different players are contantly expanding capacity to accomodate for commercial scale operations
  8. This space has also seen the rise of spin offs/startups from the academic sector
  9. Some of the players are on the lookout for novel vectors based on transposons and sendai virus to address existing challenges
  10. Especially for contract manufacturers, there is a rising opportunity from late-stage genetically modified therapies
  11. Anticancer therapies presently contribute the most to the demand for vectors

For further information, check out the report here

Read more insights at

Roots Analysis – Leaders in Pharmaceutical & Biotechnology Market Research

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
All News News

ADCs: The Excitement Continues to Build | Roots Analysis

So, another round of the World ADCs just concluded. With a stellar line up that included Alain Beck from Pierre Fabre, Thorsten Sperber from Immunomedics, Nicholas Choong form Seattle Genetics, Rakesh Dixit from BioNavigen, Trevor Hallam from Sutro Bio and many other eminent personalities, the event did live up to its expectations.

For More Insights Click Here

ADCs continue to represent a transformative approach to modern cancer treatment. At Roots Analysis, we have tracked this space for almost five years now; with over 16,000 patents, 250 molecules under development and USD 5 billion of public and private investment, there is a lot that has gone right for stakeholders engaged in this domain.

The key difference, of course, compared to what was happening a few years ago is that researchers are identifying new biological targets.

Our proprietary analysis based on a variety of parameters indicates there are several such targets that hold significant promise.

This is exactly the reason why we continue to be bullish about this market. The odds are stacked in favor of all stakeholders who have held their faith; 20% annualized growth over the next decade should not be difficult to achieve.

For further information, check out the report here

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
All News News

Targeted Protein Degradation Market: Riding on the Popularity of PROTAC, Market is set to Grow Exponentially | Roots Analysis

Over the years, the drug hunters have tried to target the tens of thousands of proteins responsible for sickness and health. But a vast majority of them have remained out of reach.

While, the scientific evolution has led to the development of potent and selective small-molecule inhibitors of protein function, but still, multiple targets of high biomedical relevance are highly challenging targets for typical small-molecule drugs. Similarly, the novel biologics, such as oligonucleotides and monoclonal antibodies have although allowed us to target some of these difficult to reach proteins, their delivery to the target site has created challenges of its own.

In this article, we will evaluate the rising popularity of the concept of targeted protein degradation in overcoming the aforementioned challenges.

For More Insights Click Here

What is Targeted Protein Degradation?

Targeted protein degradation is an emerging modality that allows access to difficult-to-treat diseases. While conventional medicines such as small molecule inhibitors and monoclonal antibodies address fewer than 20% of the proteome, targeted degradation offers a unique means to tap into the rest of the vast, unexplored proteome. Through this, a disease can be addressed by controlling the amount of a harmful protein rather than trying to modulate or inhibit its function. The control of protein levels is accomplished with a small molecule drug called a protein degrader.

What is the difference between Protein Degrader and Protein Inhibitor?

In simple words, a single protein degrader drug can eliminate multiple disease-causing proteins through proteasome degradation of the target protein. However, an inhibitor drug can only block a single disease-causing protein at a time. The figure below explains the difference:

What is the History behind Targeted Protein Degradation?

While the first small molecule PROTAC was developed in 2008, the history of targeted degradation goes back to 1992. The figure below presents an illustrative overview of the evolution of targeted protein degradation.

What are the benefits of targeted protein degradation?

Compared to conventional inhibition strategies, degradation offers several benefits, which include the opportunity to completely remove aberrant proteins and associated systemic malfunctions.

What are the key trends that are shaping up the Targeted Protein Degradation market?

As per a recent market report by Roots Analysis, more than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications. In addition, there are 25+ technology platforms available for use in therapy development efforts.

For further information, check out the report here

Read more insights at

Roots Analysis – Leaders in Pharmaceutical & Biotechnology Market Research

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
All News News

Cell and Gene Therapy Manufacturing: Rising Demand Forces Companies to Look Beyond Viral Vectors | Roots Analysis

The rise in the popularity of cell and Gene Therapy has been widely talked about in recent years. The rise in this popularity has come with its own challenges, a number of which were identified in a recent report by Root Analysis.

The challenges vary from the high cost of manufacturing to low capacity. In fact, the Roots Analysis team interviewed several stakeholders to understand their perspective about the key challenges in the vector manufacturing market. The key points from the interviews have been highlighted in this article. In the figure, I have added some of these challenges:

For More Insights Click Here

Capacity constraints remain a key challenge and have been talked about quite actively. In fact, we have seen several players invest heavily in enhancing their vector manufacturing capacity. However, one other area that has silently emerged as a potentially hot topic is the novel vectors (beyond traditional AAV vectors).

Currently, the vector manufacturing market is dominated by viral vectors, such as those based on AAV, adenovirus, lentivirus, and retrovirus. However, certain non-viral vectors, such as plasmid DNA, also hold a considerable share. Roots Analysis, in their report, talked about the rise of these non-viral vectors and identified the key emerging vectors types. Some of the vectors highlighted in the report are – alphavirus, Anc80 vector, B. longum, Listeria monocytogenes, minicircle DNA, myxoma virus, Sendai virus, self-complementary vectors (which are essentially improved versions of AAV vectors) Sleeping Beauty transposon-based non-viral vectors, and Vaccinia virus-based vectors.

In fact, several players in the biopharmaceutical industry have already begun using some of the novel vector types mentioned above for the development of their respective pipeline therapy candidates. A few of the players involved in the novel vectors space are highlighted below:

The stakeholders interviewed by Roots Analysis agreed to the rising demand for novel vector types. Here are the excerpts from some of the interviews:

“We believe that a few novel vectors, having low immunogenicities and targeting different cell types, are likely to soon be introduced into the market.  I am also aware of companies that are researching different (better) versions of adeno-associated viral vectors.” – Executive & Scientific Officer, A small-sized company based in Belgium

“We have worked with a couple of transposons and the Vaccinia viruses as vectors, the latter cannot exactly be regarded as a novel approach. I believe, transposons and Sendai virus are the only novel vector systems that are likely to soon become popular.” – Managing Director, A management consulting firm for regenerative medicines based in Japan

“To overcome the challenges associated with the production of contaminant free final product using conventional plasmids, we are developing a minicircle DNA vector, which are devoid of antibiotic resistance genes and prokaryotic plasmid components, which are crucial for the replication of constructs in bacteria.” – Project Manager and Marketing Manager, a small-sized company based in Germany

For further information, check out the report here 

Read more insights at

Roots Analysis – Leaders in Pharmaceutical & Biotechnology Market Research

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
All News News

Is genomics revolution all fun and games? How blockchain can calm data security nerves! | Roots Analysis

Have you had your genomics sequenced? If you asked this question a few years ago, people would have thought you were crazy.

However, today, genetic tests are up for sale in supermarkets! Fifteen years ago, the first ever Human Genome Project was carried out, which took more than 13 years to complete.

For More Insights Click Here

This (Human Genome Project) costed more than USD 3 billion and required joint efforts of hundreds of scientists across the globe. The completion of the project offered brilliant insights into the entire structure of the genome; including its length, sequences, protein-coding genes, structural variants and a large number of repeats and noncoding sequences which were originally believed to be ‘junk DN

Thanks to the advent of advanced NGS technologies in the past decade, it now costs under USD 1,000 and takes less than a week for an individual to have his or her genome sequenced. What’s more? They can even order a test online themselves.

Today, researchers are talking about sequencing the genomes of a million people on the planet. The rate of progress in genomics development resembles that of Moore’s Law in processor development – but it is just the beginning. With plethora of molecular level personalized data available in the hands of research groups, molecular-diagnostics companies are uniquely positioned to unravel value.

However, the entire spectrum of value can only be unlocked, if appropriate data integration and analytics capabilities are possessed by stakeholders. These include capabilities that link genetic data with other health indicators, such as medical records and even non-medical information. As the volume of data magnifies with time, and the level of analysis becomes increasingly sophisticated, both start-ups and established technology players with core competencies in advanced analytics are anticipated to venture into the genomics space. Companies such as Emerge and Ignite have already begun using genomic data linked to EMR for personalized medicine.

However, before genomic data can be utilized to its full-blown potential, additional questions regarding data privacy and security need to be answered.

Who can have access to this enormous amount of data and how do research groups, companies and government bodies ensure that genomic data doesn’t end up in the wrong hands?

World’s leading consumer genetics and research companies such as 23andMe and Ancestry.com have come under the scrutiny of Federal Trade Commission, which has a page dedicated to listing all the risks associated with sending one’s genomic data to companies like 23andMe.

In this scenario, blockchain technology has emerged as a plausible saviour for pharma’s woes. In November 2018, Encrypgen launched the world’s first genomic data marketplace, called the Gene-Chain, a cryptographically encoded ledger used to the searching, storing, buying and selling of genomic data. It is a private network, implying that users must join the community to participate. This helps in preserving the anonymity of users, create abstraction between users and their data for privacy and protection of identity, as well as process the available genetic data files through indexing.

Further, blockchain companies are offering tokens, a form of currency for exchange of data in order to incentivize the process, allowing users to have access to their products or services. With the ever-expanding and all-consuming web of hackers across the globe, protecting genomic data is one of the top concerns in the world today. Unlike credit cards and passport numbers hacks, which can be dealt with, genomic data breach is a one strike ballgame.

For further information, check out the report here

Read more insights at

Roots Analysis – Leaders in Pharmaceutical & Biotechnology Market Research

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
All News News

Growth Drivers and Roadblocks in Targeted Protein Degradation Market | Roots Analysis

In a recent article, I discussed the rise of protein degradation therapeutics and the surge in big pharma interest in this emerging space. With more than 3,600 tweets posted over the last three years to over 5,000 articles published over the last decade, the concept of protein degradation has got the right people talking.

For More Insights Click Here

In contrast to the traditional small molecule inhibitors and antibody drugs, protein degraders are designed to develop drug candidates for many intractable diseases that other therapeutic modalities cannot address.

Owing to extensive research in this domain, multiple protein-degradation-focused biotech firms have emerged with ample funding. In addition, big pharma companies, including Boehringer Ingelheim, Celgene, Novartis, and Pfizer have launched internal efforts and forged partnerships to explore the modality. Recently, Boehringer Ingelheim and the University of Dundee extended their collaboration for the development of PROTAC based drugs to treat cancer, building on the success of their ongoing alliance. Similarly, Novartis collaborated with the University of California, Berkeley to establish the Novartis-Berkeley Center for Proteomics and Chemistry Technologies. The center combines Novartis’ expertise in chemical biology with Berkeley’s expertise in covalent chemoproteomics.

To say that this space is growing would be an understatement. The potential to drug the undruggable is just far too more lucrative to let a few roadblocks come in the way. Here is a look at some of the key growth drivers and roadblocks in the targeted protein degradation space:

For further information, check out the report here

Read more insights at

Roots Analysis – Leaders in Pharmaceutical & Biotechnology Market Research

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
All News News

CMO, CMO Everywhere, Not a Single One That Fits: The Reality of Biopharma Contract Manufacturing Market | Roots Analysis

I was recently involved in a discussion with the global outsourcing manager of one of the big pharma companies. The premise of the discussion was around the criteria that big Biopharma Contract players follow for choosing a supplier for their products.

One key question that came up in the discussion was whether one-stop-shops are really the go-to companies for outsourcing. And the answer, to a certain extent, validated some of the hypotheses that we had developed internally.

For More Insights Click Here

To give you a background, in one of our market research reports, we had looked at the biopharma contract manufacturing market and identified close to 250 companies that offer biopharmaceutical contract manufacturing services. A number of these companies claim to offer end-to-end services across the value chain of the biopharmaceutical product. The majority of these one-stop-shop companies are those CDMOs that have actively made acquisitions and altered business models to get into a particular space.

However, the one-stop-shop business model doesn’t seem to be that attractive anymore. Initially, we witnessed the issues of overcapacity at some of the one-stop CMOs that made the overall operations less profitable. However, now, the one-stop-shop pitch seems nothing more than a pure marketing strategy (not to say that there are no one-stop CMOs). Except for a few top-tier CMOs (that are generally on the preferred supplier list of the majority of big pharma players), it is very difficult to validate that other CMOs actually have the same level of expertise across all the steps in the manufacturing value chain.

Horses for Courses – A better strategy?

An interesting article that I had read on this subject was by Louis Garguilo, Chief Editor, Outsourced Pharma. In his article, he presented interesting examples of why the horses for courses strategy works better than a one-stop-shop business model. One interesting section from his article that supports the argument is – If your project suffers setbacks (with a one-stop-shop) on the drug product side, your relationship on the synthesis side will also suffer. In other words, a breakdown of the relationship, or unforeseen challenges, for anyone part of your project can result in a breakdown of the entire relationship. Given the years of effort and investment that goes into developing a product, it is never a good strategy to put all your eggs in the same basket, or in other words, rely on just one supplier to decide your returns from the innovative product.

To summarize my discussion, I would say that while the biopharma companies are still figuring out what is the best business model moving forward, it is high time that companies move away from I do everything pitch to focusing on their actual unique selling points/expertise. This will make the sourcing decision much easier and establish more clarity in the industry.

For further information, check out the report here

Read more insights at

Roots Analysis – Leaders in Pharmaceutical & Biotechnology Market Research

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
All News News

Catalent’s Shopping List: Hinting Towards a One-Stop Cell & Gene Therapy CMO in Making | Roots Analysis

There appear to be no Monday blues for Catalent as the company announces the acquisition of MaSTherCell Global, a technology-focused cell and gene therapy contract development and manufacturing organization.

Following its last year’s acquisition of Paragon Bioservices (a leading viral vector developer), Catalent’s recent acquisition has extended the company’s leadership in this already crowded space.

For More Insights Click Here

Why has there been so much interest in this space?

The increasing acquisition activity in this space is heavily driven by the growing pipeline of cell-based therapies. With more than 600 candidates in development, the cell therapy space has witnessed significant interest from various stakeholders.

The development pipeline of cell-based therapies is very attractive and features a number of big pharma players. However, the manufacturing challenges associated with these therapies has acted as a roadblock.

Manufacturing cell therapies is technically and financially demanding. Therefore, despite therapy developers gradually strengthening their in-house expertise, they are also becoming increasingly reliant on contract service providers. In fact, over 100 industry players and 60 non-industry players currently claim to manufacture different types of cell therapies.

Why is Catalent acquiring so many players in gene therapy?

The acquisition of MaSTherCell is a strategic move to extend the service offerings for cell and gene therapies. Here is what the company’s CEO said about the acquisition:

“MaSTherCell extends our leadership position in the biotech industry, complements our leading gene therapy offering, and allows us to deliver comprehensive development, manufacturing, analytical, fill-finish, and clinical supply solutions for innovators across the large molecule space”

– John Chiminski, Catalent’s Chair & Chief Executive Officer

The move has allowed the company to set itself apart in the highly competitive cell and gene therapy manufacturing space.

 

For further information, check out the report here

 

Read more insights at

Roots Analysis – Leaders in Pharmaceutical & Biotechnology Market Research

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
All News News

Evolution of Cancer Diagnostics: Rise of Novel Non-Invasive Methods | Roots Analysis

When a big pharma agrees to spend millions in acquiring a drug discovery company, the world is bound to take note. The same happened earlier this year – the acquisition of Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) was a piece of big news in the drug discovery world, validating the potential of DNA encoded libraries in drug discovery.

For More Insights Click Here

The acquisition has allowed Amgen to get a team of experts adept at making and screening billions to trillions of compounds to find promising leads. And Amgen is not the only pharma company that has realized the benefits of this technology. As per a recent study by Roots Analysis, close to 100 strategic partnerships related to DNA-encoded libraries have been forged between pharma players and academic institutes and/or technology providers during the period 2010-2019. The rise in partnership activity is a clear indicator of the increasing popularity of this unique technology. Here, we will look at some of the key trends that are shaping up this industry:

What are DNA encoded libraries?

DNA-encoded compound libraries are a highly attractive technology for the discovery of small-molecule protein ligands. These compound collections consist of small molecules covalently connected to individual sequences carrying readable information about the compound structure. DNA-tagging allows for efficient synthesis, handling, and interrogation of vast numbers of chemically synthesized, drug-like compounds. Here is a perfect video describing the principle behind DNA encoded libraries.

When was the concept first introduced?

While the first small molecule PROTAC was developed in 2008, the history of targeted degradation goes back to 1992. The figure below presents an illustrative overview of the evolution of targeted protein degradation.

What are the benefits of targeted protein degradation?

The concept of  encoded libraries was introduced 25 years ago by Richard Lerner, a chemist at Scripps Research Institute California, and his colleague Sydney Brenner, co-winner of the 2002 Nobel Prize in Physiology or Medicine. The pair published a paper that’s often described as a thought experiment. They also made a small encoded library and patented the idea around the same time.

How many DNA encoded libraries are currently available to the pharma players to choose from?

According to Roots Analysis, presently, nearly 30 DNA-encoded libraries are available to various pharmaceutical companies for the purpose of drug discovery. The majority of the encoded libraries are designed to identify leads against protein pump inhibitors which are otherwise difficult to screen using traditional libraries. However, with respect to the type of pharmacological leads, over 20 libraries are designed for the discovery of small molecules, followed by macrocycles.

Which companies offer DNA encoded libraries for drug discovery?

The market is highly fragmented, featuring a mix of small-sized companies (less than 50 employees, 48%), mid-sized companies (more than 51 employees, 20%), large companies (more than 500 employees, 8%) and very large companies (more than 5,000 employees, 24%) that offer DNA-encoded libraries. Notable examples of well-established players include (in alphabetical order, no selection criteria), Amgen (through the acquisition of Nuevolution), ETH Zurich and GSK (through the acquisition of Praecis Pharmaceuticals). The recent launch of the Encoded Library (DEL) service package DELight WuXi AppTec is another example of big players entering this space.

For further information, check out the report here

Read more insights at

Roots Analysis – Leaders in Pharmaceutical & Biotechnology Market Research

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
All News News

A Pizza Hut Prescription for Gene Therapy Companies | Roots Analysis

As we enter 2020, one drug class that is set to take-off is gene therapy. With three approvals (Zolgensma® (US), Zynteglo™ (Europe) and Beperminogene Perplasmid (Japan), 2019 was a break out year for gene therapy developers.

The $16 billion-plus investment by various investors finally seems to be paying off as we enter 2020 with am.,

For More Insights Click Here

While several positives make us all very optimistic about the future of gene therapies, there are a few challenges that must be addressed before these therapies can achieve their true potential. Challenges related to pipeline development, platform selection, manufacturing, and reimbursement are amongst the top hurdles that these companies are currently facing. Also, the challenges related to supply chain and logistics are beginning to arise as these therapies reach the market.

These logistical challenges are more pronounced when products are to be distributed to international markets. Given the lack of experience specific to gene therapies in the industry, the networks may not be as developed, and delay times at ports of entry may be ruinous to products with limited shelf lives. A few other industries that have faced such logistic issues in the past are – the food delivery market, and the rental cabs or bookings market. Earlier, it had become so difficult to track the status of your pizza order. But now, with the rise of mobile applications, you can track the progress in real-time.

Let us imagine a scenario wherein you are celebrating the new year’s eve with your family. You have decided to order pizzas for the family from this amazing restaurant. You call the restaurant and place the order. The restaurant confirms your order and then the wait begins. 10 minutes….20 minutes…30 minutes pass and you have no idea where your order is. The new year celebration excitement suddenly turns to anxiety and you are worried and unsure about when can you exactly expect your pizza.

Now let us think about what happens to a patient that is eligible for a gene therapy treatment. Given the exhaustive inclusion criteria, only a limited number of patients qualify for these therapies, and once they qualify, the wait begins. And it is not just the patient who is waiting, their entire family, along with the doctors are anxiously waiting for that personalized dose of cells to be delivered at the hospital bed that can finally cure the disease. If we are ready to stretch our imaginations, this wait and anxiety that the patient faces can easily be compared to the pizza hut craving that you were having on the new year’s eve.

The solution – simple. Get an App!!

Do what every company seems to be doing these days. Make personalized therapies even more personalized. Get an app that tells the patient the whereabouts of their therapy across the supply chain. Give the patient some control and deliver not just a therapy, but an experience.

Some of the players, such as (illustrative list) Trakcel, Veeva, Be the Match BioTherapies, are already deploying solutions that can be used to efficiently manage and streamline various aspects of the complex supply chains of cell and advanced therapies. Presently, there are more than 160 innovative software-enabled systems for managing the cell and advanced therapies supply chain.

For further information, check out the report here

 

Read more insights at

Roots Analysis – Leaders in Pharmaceutical & Biotechnology Market Research

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]